Apnimed Moves Closer To Phase III With Sleep Apnea Drug

Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.

Woman wearing CPAP machine for sleep apnea
Apnimed hopes to develop the first drug to replace CPAP therapy in sleep apnea

Previous efforts to provide a drug therapy for obstructive sleep apnea patients have fallen short of the finish line but Apnimedsays it is getting closer to taking its daily, oral combination pill into pivotal Phase III trials after a pair of successful Phase II data readouts for AD109.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By 

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By 

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

More from R&D

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By 

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.